Currentblue cross blue shield - tennesseePolicy N/A

Prescription Medication and Illicit Drug Testing in the Outpatient Setting — Coverage Criteria

Coverage criteria and reimbursement policy for presumptive and definitive outpatient drug testing (primarily urine and oral fluid) for prescription medication and illicit drug monitoring; applies to outpatient providers and laboratories submitting claims to the payer.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument medical necessity and request definitive testing when presumptive results conflict with clinical presentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 7drug classes allowed for covered definitive testing

1-4/yrpresumptive urine testing frequency (low→high)

not coveredconfirmatory testing for >7 drug-class panels

not coveredspecimen validity testing

21%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

opiate false-negative rate (example)

30+procedure codes listed

Coverage Criteria and Clinical Indications

Presumptive Screening / Monitoring

Presumptive drug screening (typically urine immunoassay; qualitative, semi‑quantitative, or quantitative) meets coverage when clinical indications are present and testing frequency is documented and aligned with assessed risk.

Presumptive screening covered indications: Presumptive drug screening is covered for the following clinical situations: assessment of individuals treated for chronic non‑cancer pain when history/signs/symptoms suggest use of nonprescribed or illegal drugs; prior to initiating chronic opioid therapy; routine monitoring of individuals receiving opioid therapy (frequency based on documented risk tier); pregnant individuals at high risk when screening questions or PDMP information suggest use; newborns when there is maternal substance abuse history or altered mental status in the birthing parent; candidates for organ transplant with prior substance abuse to demonstrate abstinence; individuals with suspected or diagnosed mental illness; individuals with ADHD/disruptive behavior disorders; cancer patients on opioid medication; individuals with epilepsy; management and compliance monitoring in substance abuse treatment; and when substance abuse is in the differential diagnosis.

Random testing intervals and drug selection should be based on the individual's history, condition, treatment and documented risk; frequencies: low risk up to 1/year; moderate up to 2/year; high up to 4/year; for substance abuse treatment and early abstinence see definitive testing frequency nodes.

Definitive/Confirmatory Testing

Laboratory definitive (confirmatory) testing (GC/LC–MS based) for up to seven drug classes is covered when specifically requested with documented rationale and when one or more clinical conditions apply.

When definitive testing meets criteria: Definitive qualitative or quantitative testing (panels ≤ 7 drug classes) is covered when: (a) the presumptive screen result conflicts with the patient's history, clinical presentation, or statement (e.g., unexpected negative for prescribed medication or unexpected positive for nonprescribed/illegal drug); (b) diagnosing or monitoring a substance use disorder when accurate, reliable results are required to make treatment decisions; (c) monitoring individuals on opioid therapy for adherence and detection of non‑prescribed opioids; (d) no adequate presumptive test exists or the presumptive method does not detect the specific drug/metabolite of interest; (e) to definitively identify specific drugs within a drug family; or (f) when a definitive concentration is needed to guide clinical management.Definitive testing limited to panels of up to 7 drug classes; for SUD monitoring frequency: 0–30 days abstinence ≤1/week; 31–90 days abstinence 1–3/month (no more than 3/month); >90 days abstinence 1–3 per 3‑month period (no more than 3 per 3 months).

Definitive testing must be specifically requested by the treating physician with rationale documented in the medical record; panels >7 drug classes are not covered.

Exclusions / Not Covered

Not covered: Confirmatory/definitive testing for panels larger than seven drug classes; proprietary vendor/LDT panels (e.g., CareView360 and similar proprietary tests); specimen validity testing (e.g., creatinine, specific gravity, pH, oxidant/adulterant screens, genetic identity assays); same‑day testing of the same drug/metabolite from two different specimens (e.g., blood and urine); more than one presumptive test result per patient per date of service; blanket or standing orders for all patients; and duplicate point‑of‑care and reference laboratory testing on the same specimen are not reimbursed.

These items DO NOT MEET COVERAGE CRITERIA per policy.

Clinical utility contexts

Testing may be reasonable and clinically useful in specific settings and scenarios supported by evidence and guideline references.

Supported clinical settings: Settings where drug testing is considered clinically useful include: drug treatment programs (to monitor abstinence and inform treatment plans); pain management programs (baseline assessment and ongoing compliance monitoring); psychiatric treatment when substance use may contribute to presentation (e.g., acute psychosis); select preoperative assessments such as joint arthroplasty risk evaluation; and other situations where testing would alter management (e.g., unexplained toxicity, potential drug‑drug interactions).

Studies show UDT can detect undisclosed use and support improved compliance in some programs, though evidence of impact on misuse reduction is variable.

Testing workflow and method selection

Recommended workflow emphasizes an orthogonal approach: start with presumptive testing and use definitive methods selectively.

Confirmation workflow: Begin with an initial presumptive immunoassay (POC or laboratory‑based) and perform definitive confirmatory testing (GC‑MS, LC‑MS, or LC‑MS/MS) for positive results that will influence major clinical decisions or for any results inconsistent with clinical expectations. Clinicians should be aware of immunoassay limitations including false positives and false negatives and consult package inserts and laboratory personnel as needed.

Definitive MS‑based assays are the gold standard and detect more compounds; EIAs have reported sensitivities ~78.5% overall and notable false‑negative rates (e.g., ~21% for opiates in one study).

Quantitative monitoring limitations

Quantitative urine testing has limited ability to determine dosing or adherence and must be interpreted cautiously.

Interpreting quantitative/normalized urine levels: Quantitative urine concentrations frequently do not reliably indicate medication dose or adherence because of inter‑individual pharmacokinetic, pharmacodynamic, and pharmacogenetic variability; commercial normalization algorithms have shown limited correlation with administered doses and often exclude variant metabolizer phenotypes.

Quantitative testing may be useful in select situations (variant metabolism, impurity/contamination, complex cases, or to rule out alternative exposure sources) but is not recommended for routine dose adjustment or adherence determination.

Monitoring and testing criteria

Coverage aligns with guideline recommendations for baseline testing, risk‑stratified ongoing monitoring, and preference for definitive methods when indicated.

Baseline testing: Perform baseline urine drug testing prior to initiating opioid therapy for chronic pain.

Consensus guideline recommendations (e.g., Argoff et al.) support baseline UDT.

Ongoing monitoring frequency: Risk‑stratified monitoring: Low‑risk patients—at least annually or every 6–12 months; Moderate‑risk patients—at least 2 times per year or every 3–6 months; High‑risk patients—3 or more times per year or every 1–3 months; additional monitoring as clinically indicated (including testing at time of visit for aberrant behavior).

Frequencies based on guideline panels (Argoff et al., AACC, AAFP, FSMB, etc.).

Test modality preference: Use definitive MS‑based testing (GC‑MS, LC‑MS, LC‑MS/MS) as the preferred method for baseline and ongoing monitoring in most chronic pain patients; immunoassays may be acceptable for low‑risk patients or when required by payer/institutional policy.

Guideline consensus supports definitive testing for accuracy and sensitivity.

Monitoring and confirmation criteria

Testing is covered when it follows guideline‑based monitoring and confirmatory strategies, with documentation and specimen validity practices.

Baseline and ongoing monitoring

Risk tiers: Low risk: testing quarterly to semiannually; Moderate risk: 2–4 times/year; High risk: monthly or ≥4/year; aberrant behavior: test at visit.examples in guideline chunks
Organizational recommendations vary; document rationale in the record.
Confirmatory testing: Obtain GC‑MS or LC‑MS/MS definitive testing for any presumptive result inconsistent with clinical expectations or unexplained positive/negative POC results prior to major clinical decisions.N/A
Strong recommendation in multiple guidance documents.

Recommended Indications for Toxicology Testing

Guidelines and professional societies identify specific clinical indications where toxicology testing is recommended or useful.

Behavioral health and opioid treatment: Toxicology screening is recommended prior to admission to opioid treatment programs (address benzodiazepine use via cessation or taper) and as part of opioid therapy risk assessment, with PDMP checks and documented rationale.

AATOD and other task forces recommend these actions.

Acute/psychiatric/neurologic presentations: Consider urine or blood toxicology in acute psychosis, suspected intoxication/withdrawal/overdose, and pediatric status epilepticus of unclear etiology to assist diagnosis and immediate management.

WHO, WFSBP, AACAP, and AAN guidance support testing in these scenarios.

Pregnancy and reproductive‑age women: Screen pregnant women using validated screening tools at the first prenatal visit; perform urine drug testing only with informed consent and in compliance with state laws; routine universal urine testing is controversial.

ACOG recommends validated screening tools and consent; state law considerations apply.

This policy applies to outpatient presumptive and definitive drug testing for monitoring prescription and illicit drug use and does not address legally mandated or forensic testing, employment-related/occupational testing, routine physical examinations, or testing performed solely as part of urgent/emergency care or routine behavioral health assessments. Coverage determinations remain dependent on the member's benefit coverage at the time of the request and applicable state or federal regulations will govern when in conflict with this policy.

Routine broad toxicology screening for acute emergency department management generally has limited clinical utility and may be unnecessary in many cases; large retrospective series and systematic reviews demonstrate variable impact on management and, in some analyses, substantial testing was judged 'unnecessary and wasteful.' Use in the ED should therefore be reserved for situations where results are expected to change immediate clinical care.

Quantitative definitive urine testing has important niche uses but should not be relied upon to determine patient dosing or to prove adherence because urine concentrations are affected by pharmacokinetic, pharmacodynamic, and pharmacogenetic variability; published studies report low correlation between unadjusted urine levels and dose and question commercial algorithm accuracy.

Routine reliance on the SAMHSA-5 panel alone is discouraged; guideline groups recommend tailoring panels to the clinical context and adding analytes when presumptive methods do not detect the drug(s) of interest or when definitive identification is needed.

There is ongoing controversy about routine urine drug screening: a positive result alone is not diagnostic of an opioid use disorder and a negative result does not exclude sporadic use. Professional guidance therefore emphasizes using validated screening tools, understanding test limitations, and obtaining confirmatory testing when results will affect major clinical decisions.

Some laboratories offer laboratory-developed tests (LDTs); these are regulated under CLIA as high-complexity tests and are not FDA-approved. The policy notes LDT status but does not state an explicit coverage decision based solely on FDA approval status—coverage may be influenced by payer or government regulations.

Immunoassay screens can be affected by assay interferences and false positives (for example, diphenhydramine, tramadol, some NSAIDs and other agents have been reported to cause false results). Clinicians should reference assay package inserts and consult laboratory personnel when interpreting unexpected presumptive results and consider confirmatory definitive testing as appropriate.

Specimen validity testing (creatinine, specific gravity, pH, oxidant/adulterant screens), use of proprietary vendor algorithms/panels, and confirmatory testing for panels larger than seven drug classes are explicitly described in the policy as not meeting coverage criteria; such testing and proprietary panels are therefore excluded from coverage under this policy.

Clinical Indications Eligible for Coverage

Monitoring clinical populations (chronic opioid therapy, pre-initiation assessment, suspected misuse, pregnancy, transplant candidates, substance use treatment, mental health contexts, ADHD, cancer, epilepsy)

Chronic opioid therapy and related populations: Covered clinical populations for monitoring include: patients on chronic opioid therapy (baseline and ongoing risk‑stratified monitoring); individuals prior to initiating chronic opioid therapy; patients with suspected misuse or nonprescribed/illicit use; pregnant individuals at high risk and newborns with maternal substance use history; organ transplant candidates with prior substance abuse; individuals in substance use treatment programs; patients in psychiatric care where substance use is suspected; individuals with ADHD or disruptive behavior disorders; cancer patients receiving opioids; and individuals with epilepsy when substance use is in the differential.

Monitoring frequency must be documented and based on risk assessment; definitive testing limited to panels ≤7 drug classes.

Monitoring compliance and baseline risk assessment in pain management, drug treatment, and psychiatric care

Monitoring compliance and baseline risk assessment: UDT is supported for baseline risk assessment and ongoing monitoring in pain management programs, drug treatment programs, and psychiatric care to identify noncompliance and undisclosed use; frequency and panel selection should be tailored to patient risk and documented clinical need.

Testing Frequency and Limits

Presumptive and definitive testing frequency tiers — low/moderate/high risk and substance abuse treatment monitoring intervals

Presumptive monitoring (chronic opioid therapy)Low risk: up to 1 test per year; Moderate risk: up to 2 tests per year; High risk: up to 4 tests per year (also test at time of visit for aberrant behavior)

Definitive testing for SUD monitoring (abstinence-based)0–30 days abstinent: random definitive testing ≤1/week; 31–90 days: 1–3/month (≤3/month); >90 days: 1–3 every 3 months (≤3 per 3-month period)

Substance abuse treatment (OTPs/Drug Courts)Initial frequent/random testing (e.g., weekly) with decreasing frequency as stable; some programs (e.g., NY State Drug Courts) may require up to twice-weekly testing and OTPs at least 8 random tests/year

Aberrant behaviorTesting at time of visit meets coverage criteria (lost prescriptions, early refill requests, multiple providers, intoxication, unauthorized dose escalation)

UDT frequency guidance (urine)

Procedure Codes and Reimbursement Guidance

Not reimbursed codesmixedNot Covered

Any AMA definitive drug class codes

Any AMA definitive drug class codes are not reimbursed (document states 'Any AMA definitive drug class codes' IS NOT REIMBURSED).

Not reimbursed codes - additional not reimbursed itemsmixedNot Covered

Same-day duplicate specimen testing	Same-day testing of the same drug or metabolites from two different samples (e.g., both a blood and a urine specimen) by either presumptive or definitive analyses is not reimbursed.
Multiple presumptive tests per date of service	More than one presumptive test result per patient per date of service regardless of number of billing providers is not reimbursed (includes duplicate POC and reference lab presumptive testing on same specimen).
Blanket or standing orders	Blanket orders or routine standing orders for all patients in the physician's practice are not reimbursed.

Presumptive drug test CPT CodesCPT

80305	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay), includes sample validation when performed, per date of service.
80306	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (eg, utilizing immunoassay).
80307	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay), chromatography, and mass spectrometry either with or without chromatography; includes sample validation when performed, per date of service.

Proprietary/PLA/U codes and vendor panelsCPT

0007U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA (Proprietary test: ToxProtect).
0011U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range (Proprietary test: Cordant CORE™).
0051U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected (Proprietary test: UCompliDx).
0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges (Proprietary test: AssuranceRx Micro Serum).
0079U	Comparative DNA analysis using multiple selected SNPs, urine and buccal DNA, for specimen identity verification (Proprietary test: ToxLok™).
0082U	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive testing by instrument chemistry analyzer, urine, report of presence or absence of each drug or metabolite (Proprietary test).
0093U	Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected (Proprietary test: ComplyRX).
0227U	Drug assay, presumptive, 30 or more drugs or metabolites, urine, LC-MS/MS using multiple reaction monitoring (MRM), includes sample validation (Proprietary Test: Comprehensive Screen).
0328U	Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative LC-MS/MS, includes specimen validity and algorithmic analysis (Proprietary test: CareView360).

Definitive drug testing G-codesHCPCS

G0480	Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish structural isomers, with stable isotope/internal standards and method-specific calibration; qualitative or quantitative, includes specimen validity testing; 1-7 drug classes.
G0481	Drug test(s), definitive, same methods as G0480; 8-14 drug classes.
G0482	Drug test(s), definitive, same methods as G0480; 15-21 drug classes.
G0483	Drug test(s), definitive, same methods as G0480; 22 or more drug classes.
G0659	Drug test(s), definitive, utilizing drug identification methods but performed without method- or drug-specific calibration, without matrix-matched QC, or without use of stable isotope internal standards; qualitative or quantitative, any number of drug classes; includes specimen validity testing.

Detection windows examples (amphetamines, marijuana, benzodiazepines)

Amphetamines detection windowAcute exposure: ~1–2 days; chronic exposure: ~2–4 days

Marijuana (THC) detection windowAcute exposure: ~1–3 days; chronic exposure: >1 month

Benzodiazepines detection windowMost benzodiazepines: ~1–5 days; diazepam and some agents: up to 2–30 days depending on agent

THC immunoassay cutoff commonly referenced (50 ng/mL)

Common THC immunoassay cutoff50 ng/mL (federal cutoff frequently referenced for urine immunoassays)

Lower confirmatory cutoffs

Provider Requirements, Documentation, and Operational Guidance

Documentation Required

Benefit verification and documentation

Verify member benefits and document medical necessity before ordering drug testing. Confirm coverage limitations (e.g., definitive testing limited to panels ≤7 drug classes; specimen types covered) and note that government policies (LCD/NCD/Medicaid) take precedence when conflicts exist. Ensure prior authorization requirements (if any) are checked through the payer prior to testing and record the benefit verification in the medical record.

Confirm member-specific coverage and any PA requirements at time of service
Document benefit verification (date, representative, reference number) in patient chart

Note

Definitive testing preferred; immunoassay acceptable in limited circumstances

Use definitive (confirmatory) testing (GC‑MS, LC‑MS, LC‑MS/MS) as the preferred method for baseline assessment and most monitoring of patients on opioid therapy or when clinical decisions depend on accurate identification/quantitation of drugs. Immunoassay (laboratory or POC) may be acceptable for initial screening or for low‑risk patients when institutional/payer rules permit, but positive or clinically discordant immunoassay results should prompt definitive, orthogonal confirmation.

Ordering, Consent, and Operational Requirements

Note

Order definitive testing only when specifically requested with documented rationale

Definitive testing must be specifically requested by the treating physician with the rationale documented in the medical record and the requested testing frequency justified by clinical need and risk assessment.

Physician must document rationale when ordering definitive (confirmatory) testing.
Testing frequency should be justified based on individual clinical history and risk.

Note

Be ready to order confirmatory definitive testing for critical POC results

Be prepared to order confirmatory definitive testing (GC‑MS/LC‑MS/MS) for positive or clinically critical POC/presumptive results.

POC positives typically require confirmatory definitive testing before major management changes.

Documentation Required

Document indication and clinical judgment when ordering tests

Exclusions and Services Not Reimbursed

Specimen validity testing (e.g., urine specific gravity, creatinine, pH, oxidant/adulterant screens), proprietary vendor tests, and definitive/confirmatory testing for panels that exceed seven drug classes are listed as not meeting coverage criteria and will be denied when billed for coverage.

Routine drug-of-abuse testing ordered for general acute ED management without a specific clinical indication is of limited value and may be considered unnecessary; such screening is not supported as a routine covered service in the absence of an indication that the result will change immediate management.

Quantitative testing that purports to determine patient compliance or to calculate administered dose using commercial algorithms is not supported due to marked interindividual variability and limited correlation between urine concentrations and dosing; such algorithm-driven quantitative dosing decisions are not covered.

Quantitative urine testing performed solely to evaluate adherence or to determine dose adjustments is not supported as a routine covered indication; quantitative assays may be appropriate in select complex cases (variant metabolism, impurity exposure, or when concentrations will inform management).

Universal, routine urine drug screening without a documented clinical indication is controversial and not specifically endorsed by major bodies; ACOG recommends screening with validated tools and informed consent rather than routine universal urine testing in pregnancy.

The document does not list explicit test-type exclusions beyond the not-covered items above; it notes that laboratory-developed tests are not FDA-approved and that payer or government rules may affect coverage of such tests.

Definitions, Background, and Testing Modalities

Drug testing is used to detect non-prescribed and illicit drug use and to monitor adherence to prescribed therapies across settings such as pain management, addiction treatment, psychiatric care, preoperative risk assessment, and select acute presentations where substance exposure is suspected. Urine is the most commonly used matrix because of cost and detection window; definitive testing (chromatography–mass spectrometry) is recognized as the most specific approach when results will guide important clinical decisions.

Definitions — presumptive vs definitive testing definitions and differences

Presumptive (screening) testing — definitionQualitative or semi-quantitative screening typically performed by immunoassay (POC or lab-based) to detect drug classes; rapid results but lower sensitivity/specificity than definitive methods

Definitive (confirmatory) testing — definitionLaboratory-based chromatographic and spectroscopic methods (GC, LC with MS or tandem MS) that identify specific drugs/metabolites and can be qualitative or quantitative

Key differencePresumptive tests detect classes and may yield false-positives/negatives; definitive tests provide higher specificity and detect individual drugs/metabolites

Evidence, Guidelines, and References

This policy excerpt does not include specific prior authorization requirements; reviewers should note that coverage decisions are subject to an individual member’s benefits and that no explicit payer prior authorization rules are described in these reference sections.

Multiple professional guidelines and review articles support the use of urine drug testing for monitoring patients on opioid therapy and in addiction medicine; references cited include AACC practice guidance, ASAM guidance, AATOD recommendations, and others that endorse risk‑stratified testing and confirmatory methods when clinically indicated.

The policy cites additional literature supporting urine drug testing in pain management and addiction medicine, including guideline summaries and systematic reviews that discuss testing performance, clinical contexts, and limitations relevant to monitoring and treatment decisions.

Assay performance, package inserts, and peer‑reviewed reports are cited regarding limitations and interferences for common immunoassays and point‑of‑care tests; clinicians are advised to consult assay documentation and laboratory experts when interpreting unexpected results.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument medical necessity and request definitive testing when presumptive results conflict with clinical presentation.

SourceLink

On This Page

Confirmatory testing: Obtain definitive confirmatory testing for any immunoassay result that is inconsistent with clinical expectations before making long‑term management changes.

Strong recommendation from multiple societies.

Alternative matrices: Urine is the preferred matrix for routine monitoring; serum/plasma or oral fluid can be acceptable alternatives in special circumstances (e.g., anuria, dialysis, or when specific analytes are targeted); hair testing may be used to detect longer‑term use where clinically appropriate.

Matrix selection should be driven by clinical context and test performance.

Quantitative testing use:

Reserve quantitative definitive testing for assessment of variant metabolism, pharmaceutical impurities, complex cases, confirmation of spiked samples, or to rule out alternate exposure sources; do not use quantitative urine testing routinely to determine dosing or routine adherence.

ASAM and other guidance caution against routine use of quantitation for adherence/dosing decisions.

Specimen validity: Perform and document specimen validity testing (creatinine, specific gravity, pH, adulterant/oxidant screens) and pursue additional testing or specimen rejection when adulteration indicators or abnormal specimen characteristics are present.N/A

Federal workplace guidance and other sources list adulteration thresholds (e.g., pH <4 or >11, nitrite >500 mcg/mL, chromium >50 mcg/mL).

General medical and veteran populations: In general medical and mental healthcare settings, annual screening for unhealthy alcohol use (e.g., AUDIT‑C) and targeted drug testing when indicated is recommended; testing should be timely, confidential, and clinically actionable.

VA/DOD and WHO guidance referenced.

Evidence shows UDT can identify noncompliance and illicit use though impact on misuse reduction is variable across studies.

Preoperative risk assessment (e.g., joint arthroplasty) as covered indication

Preoperative risk assessment: Preoperative urine drug screening may be used for risk assessment prior to procedures such as joint arthroplasty to detect undisclosed opioid or illicit drug use and inform perioperative planning.

Community practice data demonstrated notable rates of positive UDT without prescription history; consider limitations of urine detection windows when interpreting results.

Baseline and ongoing monitoring of patients prescribed opioids or controlled substances (chronic pain, preoperative risk, high-risk patients)

Baseline and ongoing monitoring for controlled substances: Perform baseline UDT prior to initiating opioid or other controlled substance therapy and continue risk‑stratified monitoring for high‑risk patients, preoperative assessments, and other high‑risk contexts to detect prescribed medication presence, non‑prescribed/illicit drugs, and to inform clinical management and risk stratification.

Use definitive testing when results will affect major clinical decisions; document frequency and rationale in the medical record.

Baseline assessment before starting chronic opioid therapy and periodic monitoring; definitive testing for unexpected POC results

Baseline assessment and periodic monitoring: Baseline assessment is required before starting chronic opioid therapy. Periodic monitoring using presumptive testing with reflex to definitive testing for unexpected results is indicated; definitive testing is recommended for unexpected POC results and when results will affect major clinical decisions.

ASIPP, ASAM and other societies recommend baseline POC immunoassay followed by risk‑based monitoring and confirmatory testing when results are inappropriate or unexplained.

Emergency and acute scenarios supported (overdose, withdrawal, acute psychiatric, pediatric status epilepticus)

Emergency and acute scenarios: Testing is supported in emergency and acute scenarios where intoxication, withdrawal, or overdose is suspected, for acute psychiatric presentations when substance exposure cannot be ruled out, and for pediatric status epilepticus of unclear etiology.

WHO, WFSBP, AACAP and AAN guidance support testing in these scenarios.

Pre-admission evaluation for opioid treatment programs and risk assessment

Pre‑admission evaluation for opioid treatment programs: Perform toxicology screening as part of pre‑admission evaluation to opioid treatment programs; address concurrent benzodiazepine use by cessation or taper prior to admission and use PDMP checks as recommended.

AATOD and other task forces recommend these measures; confirmatory testing may be used when indicated.

Guideline-backed monitoring contexts (opioid therapy, addiction medicine, prescription drug monitoring)

Guideline‑backed monitoring contexts: Numerous guideline bodies support UDT and confirmatory testing in opioid therapy, addiction medicine, and prescription drug monitoring programs; testing should be used alongside other clinical tools and documented risk assessments.

References include Argoff et al., AACC, ASAM, ASIPP, VA/DOD and other professional societies.

Monitoring drug therapy in pain management and addiction medicine

Monitoring in pain management and addiction medicine: Use urine drug testing (presumptive with reflex to definitive) to monitor drug therapy in pain management and addiction medicine settings; tailor panels and frequency to clinical context and risk, and document interpretation and follow‑up actions in the medical record.

Multiple guideline and review articles support this approach; evidence for effect on misuse reduction is mixed and documentation is essential.

Low risk (urine UDT)Every 6–12 months

Moderate risk (urine UDT)Every 3–6 months

High risk (urine UDT)Every 1–3 months (or more frequently as clinically indicated)

Risk-stratified frequencies for urine/oral fluid per multiple societies

Guideline consensus (examples)Risk-stratified frequencies described by multiple societies: low risk quarterly/biannual; moderate 2–4/year; high risk monthly or more; OTPs and drug courts may require more frequent/random testing

Oral fluid alternativeSAMHSA and other bodies include oral fluid as alternate matrix with risk-based frequency similar to urine when appropriate

Program-specific requirementsOpioid treatment programs: at least eight random tests/year; Drug courts: may require up to twice-weekly testing

Random/unannounced testingASAM and others recommend random, unannounced testing rather than scheduled testing for SUD monitoring

Example program participant testing and special program frequencies

Drug court participantsSome programs (e.g., NY State Drug Courts) may require toxicology testing twice weekly; testing schedules determined by program rules

Opioid treatment program (OTP) participantsInitial frequent/random testing (often weekly) with decreasing frequency as patient stabilizes; at least eight random tests/year cited

Pre-admission to specialized programsToxicology screening recommended prior to admission to OTPs; address benzodiazepine use (cessation or taper) per AATOD guidance

Prenatal urine toxicology screening timing

Timing for prenatal screeningScreening for substance use should be part of comprehensive obstetric care and performed at the first prenatal visit using validated tools; urine toxicology testing with informed consent as indicated

Follow-up during pregnancyPeriodic urine toxicology screening may be performed as clinically indicated and in compliance with state law

Documentation and consentObtain informed consent prior to maternal drug toxicology testing; use validated verbal screening tools per ACOG

Frequency limits — numeric summary

Presumptive monitoring numeric limitsLow risk: up to 1/year; Moderate risk: up to 2/year; High risk: up to 4/year

Definitive SUD monitoring limits0–30 days abstinent: ≤1/week; 31–90 days: ≤3/month; >90 days: ≤3 per 3-month period

Program-specific frequency examplesOTPs: at least 8 random tests/year; Drug courts: up to twice-weekly testing as program requires

Alternate confirmatory initial test cutoffs for THC noted at 2 ng/mL (confirmatory technologies) in SAMHSA guidance

POC strip exampleRapid chromatographic immunoassays (e.g., THC One Step) detect delta-9-THC metabolite at 50 ng/mL cutoff

PCP immunoassay cutoff example (25 ng/mL)

PCP immunoassay cutoff example25 ng/mL (CEDIA®/FDA-approved immunoassays report 100% reactivity at 25 ng/mL)

Interfering substancesMultiple compounds (e.g., tramadol, dextromethorphan, diphenhydramine, alprazolam) can interfere with PCP immunoassays; positives should be confirmed by GC/MS

POC assay noteFDA-approved Wondfo PCP urine test identifies PCP at 25 ng/mL but is considered preliminary and requires confirmatory GC/MS

Cocaine metabolite assay cutoff example (150-300 ng/mL)

Cocaine metabolite (benzoylecgonine) cutoffImmunoassay concentration cutoffs reported at ~150–300 ng/mL (DRI Cocaine Metabolite Assay example)

Metabolite testedBenzoylecgonine is the primary urinary metabolite targeted by assays

Detection window noteCocaine metabolite benzoylecgonine detectable for several days depending on use frequency and intensity

SAMHSA oral fluid initial test cutoffs examples

SAMHSA oral fluid initial test cutoffs (examples)THC: 2–4 ng/mL; Cocaine/Benzoylecgonine: 8–15 ng/mL; Codeine/Morphine: 15–30 ng/mL; Phencyclidine: 10 ng/mL; Amphetamine/Methamphetamine: 25–50 ng/mL

SAMHSA referenceCutoffs and guidance derived from SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs

Use caseOral fluid cutoffs apply to initial screening technologies and differ from urine cutoffs; confirmatory testing uses method-specific cutoffs

Adulteration thresholds used as specimen validity triggers

Adulteration/specimen validity thresholdspH <4 or >11; nitrite concentration >500 mcg/mL; chromium concentration >50 mcg/mL; presence of halogens, surfactants, pyridines or unusual creatinine/specific gravity may invalidate specimen

Specimen validity actionsSpecimens with these indicators may be considered invalid and trigger additional testing or rejection per federal workplace guidance

Documentation requirementSpecimen validity testing (creatinine, specific gravity, pH, oxidant) must be performed and documented for federal workplace programs and may be required by some programs

Drug class count thresholds for G0480-G0483

G0480 — drug class count1–7 drug classes

G0481 — drug class count8–14 drug classes

G0482 — drug class count15–21 drug classes

G0483 — drug class count22 or more drug classes

Definitive testing is preferred for baseline opioid use assessment and ongoing monitoring in chronic pain patients
Immunoassays acceptable for initial/low‑risk screening but require confirmatory testing when results are unexpected or will alter management
Avoid definitive panels >7 drug classes — these exceed coverage limits and may be denied

Billing Rule

Use enumerated CPT/HCPCS codes for claim submission

Submit claims using the appropriate, enumerated CPT/HCPCS code that matches the test performed and the number of drug classes reported. Include documentation tying the selected code to the test method (e.g., G0480 for definitive 1–7 drug classes using validated GC/MS or LC/MS methods).

Use G0480/G0481/G0659 as applicable for definitive testing and follow payer guidance
Do not bill AMA definitive drug class codes that the policy excludes from reimbursement

Denial Risk

Definitive testing for panels larger than seven drug classes

Definitive testing panels larger than seven drug classes are not covered and will be denied. Proprietary multi‑analyte tests and some high‑coverage panels (e.g., certain commercial >7‑class assays) may be excluded from coverage; verify coverage before ordering.

Confirmatory/definitive panels >7 drug classes DO NOT MEET COVERAGE CRITERIA
Proprietary tests (e.g., CareView360) may be non‑covered — check specific test reimbursement status

Note

Testing has limited clinical utility for general acute management

Recognize that drug testing has limited utility in many acute care settings; order testing when it will inform management (e.g., pain management, substance use disorder monitoring, pre‑treatment assessment) rather than as routine screening in the ED or for general acute presentations.

Avoid routine or blanket orders for all patients; testing should be clinically indicated and documented
Consider testing utility in context (pain clinic, addiction treatment, certain psychiatric or seizure presentations)

Documentation Required

Repeat/confirmatory testing when indicated

Repeat or confirmatory testing should be performed when presumptive (immunoassay) results are inconsistent with the patient’s medication history, clinical presentation, or when a negative result would not be expected (e.g., negative for prescribed opioid). Follow orthogonal testing: initial immunoassay screening followed by MS‑based confirmation when indicated.

Repeat testing when POC or lab immunoassay results are discordant with clinical expectations
Use chromatography/mass spectrometry methods for confirmatory testing and specify the drug of interest when repeating

Prior Authorization

Abnormal specimen handling risks and required follow-up

If a specimen exhibits abnormal characteristics (unusual color/odor, semi‑solid, non‑recovery/internal standard failure, or adulteration indicators such as extreme pH, high nitrite, chromium, halogens, surfactants), document findings, perform appropriate specimen‑validity testing (creatinine, specific gravity, pH, oxidants), and pursue additional testing or procedures per federal/workplace protocols. Note that some specimen validity tests are not covered.

Document any abnormal specimen characteristics and actions taken
Perform and record specimen validity tests (creatinine, specific gravity, pH, oxidant) when indicated
Be aware that federal workplace criteria require additional approvals and testing for abnormal specimens

Denial Risk

Conflict with government policy may trigger denial

When a payer or government policy (e.g., Medicare/Medicaid LCD/NCD, federal workplace rules) conflicts with this policy, the government policy governs and may trigger denial if the other policy is applied. Verify and follow applicable Medicare/Medicaid and state rules for the member.

If conflict exists, apply the relevant government coverage determination (LCD/NCD)
Check member’s state Medicaid rules and federal program requirements before ordering

Documentation Required

Medical record documentation and coding linkage

Document clinical rationale comprehensively in the medical record: relevant history, focused exam, indication for testing, results of prior presumptive tests, clinical interpretation, and how results will impact management. Include benefit verification, PA reference (if applicable), and linkage between documentation and billed CPT/HCPCS codes.

Medical record must show clinical reason and necessity for each test ordered
Retain documentation of benefit verification and any payer communications
Correlate test method and result interpretation in the chart

Documentation Required

Documentation for quantitative/definitive testing interpretation

When using quantitative or definitive testing, document factors that can influence interpretation (pharmacokinetic/pharmacogenetic variability, timing of last dose, urine concentration adjustments such as creatinine or specific gravity) and include lab method details and validation. Quantitative results should be interpreted cautiously and in clinical context.

Record dosing history, timing of last dose, and any factors (age, renal function) affecting drug levels
Document urine concentration adjustments (creatinine, specific gravity) when interpreting quantitative urine levels

Documentation Required

Testing method and laboratory validation documentation

Document the testing method, laboratory validation, and CLIA status for laboratory‑developed tests (LDTs). Ensure methods (immunoassay, GC‑MS, LC‑MS/MS) and any limitations are recorded in the medical record to support the selected CPT/HCPCS codes and clinical decisions.

Include lab method (e.g., GC‑MS, LC‑MS/MS), whether method is qualitative or quantitative, and LDT/CLIA details
Document that definitive methods meet technical standards cited in G0480/G0481 descriptions

Billing Rule

Coding and test documentation to support claims

Maintain coding and test documentation to match the billed procedure code. Describe the test performed (presumptive vs definitive), number of drug classes, specimen type, and any specimen validity testing performed so claims align with clinical records and payer rules.

Ensure procedure coding reflects the method, number of classes, and specimen (urine, oral fluid; blood only for anuric CRF per policy)
Avoid billing multiple presumptive tests for the same patient/date of service or same specimen type

Note

Cited literature on interpretation and utility

Clinical literature informs interpretation and operational best practices but does not replace required documentation. Reference guideline sources (AACC, CDC, ASIPP, FSMB, ACOG, VA/DoD) for testing algorithms, interpretation caveats, and monitoring frequency to support clinical decisions.

Use guideline recommendations to justify testing frequency and method selection in the record
Cite guideline evidence in the chart when using non-routine testing or monitoring algorithms

Note

Recommend orthogonal testing approach

Recommend an orthogonal approach: perform an initial immunoassay for rapid screening (POC or lab) then confirm unexpected or clinically significant findings with MS‑based definitive testing. This balances rapid clinical decision needs with accuracy for management decisions.

Initial immunoassay acceptable for timely clinical decisions; confirm positives or discordant results with definitive testing
Document rationale for initial screening and for any subsequent confirmatory testing

Documentation Required

Actions when POC or laboratory immunoassay results are inconsistent

When point‑of‑care (POC) or laboratory immunoassay results are negative for a prescribed opioid or otherwise inconsistent with the clinical picture, repeat testing using chromatography/mass spectrometry and specify the drug of interest. For positive non‑prescribed or illegal drug findings, institute repeat testing and appropriate clinical follow‑up.

Repeat with definitive testing when POC/lab immunoassay is negative for a prescribed opioid
For positive unexpected results, perform confirmatory testing regularly per guidelines

Note

Baseline POC testing with risk‑based confirmatory follow‑up

Follow ASIPP and related guidance: perform baseline POC immunoassay at initiation of opioid therapy, then risk‑based follow-up with random POC immunoassay (1–3 months for initial compliance, then 6–12 months if appropriate). Unexplained or inappropriate POC results should trigger confirmatory testing and closer follow‑up.

Baseline POC immunoassay recommended prior to initiating opioid therapy
Escalate to definitive testing for unexplained or discordant results and increase monitoring frequency for higher‑risk patients

Prior Authorization

Pre‑admission and prenatal screening actions

For pre‑admission to opioid treatment programs and prenatal screening, follow specialty guidance: address benzodiazepine cessation/tapering before OTP admission, screen prenatal patients per ACOG recommendations (universal verbal screening and testing per state law), and use confirmatory testing when results will affect care or program admission.

Ensure benzodiazepine use is addressed before OTP admission and consider confirmatory testing per AATOD guidance
Perform prenatal screening consistent with ACOG and state consent/law requirements; document patient consent and follow‑up actions

Note

No other provider actions specified in references

No specific additional provider actions or step‑therapy requirements are specified in the reference lists beyond those above; providers should follow payer‑specific operational rules and the documentation, coding, and testing guidance in this section.

If no explicit PA or step therapy is listed, verify member benefits and document that verification
Be aware that some specimen validity tests and proprietary assays are not covered

Document the indication for testing (baseline, risk‑based monitoring, follow‑up of unexpected result) and the clinical judgment supporting the order.

Include indication and how frequency aligns with documented risk tier.

Note

Order per clinical judgment and program‑specific rules (OTPs, federal programs)

Order testing based on clinical judgment and guideline risk stratification; opioid treatment programs and federal programs have specific pre‑admission and additional testing requirements.

OTPs may require benzodiazepine management and routine toxicology checks; federal programs follow HHS/SAMHSA panels and validity testing rules.

Documentation Required

Obtain informed consent and use validated tools for prenatal testing

Obtain informed consent prior to maternal drug toxicology testing and use validated screening tools for prenatal contexts as recommended by ACOG and SOGC.

Screen at first prenatal visit with validated tools and obtain consent before urine drug testing.

Note

Follow applicable government policies when they differ from this policy

When government policies differ (e.g., Medicare/Medicaid LCDs/NCDs or state Medicaid), those policies govern ordering and coverage decisions.

Note

No explicit restrictions on who may order testing stated in excerpt

Orderers and clinical contexts (pain management, addiction medicine, workplace testing) are described in cited literature, but no explicit list of authorized orderers is provided in the excerpt.

Immunoassay-based screens may lack sufficient sensitivity for certain monitoring purposes; while the policy does not list specific immunoassay exclusions, it recommends definitive chromatographic/mass spectrometry methods (GC-MS, LC-MS, LC-MS/MS) when higher sensitivity and specificity are required for baseline or ongoing monitoring.

Definitions — forensic testing definition and exclusion

Forensic testing — definition and exclusionTesting used for legal proceedings requiring secondary confirmatory testing; forensic testing is excluded from this clinical outpatient policy

ImplicationClinical coverage criteria do not apply to legally-mandated forensic testing, which follows separate protocols

Definitions — therapeutic drug monitoring (TDM) exclusion

Therapeutic drug monitoring (TDM) — definitionSampling of plasma/serum drug levels to determine optimal dosing; TDM is outside the scope of this policy

Coverage noteThis policy addresses clinical toxicology for outpatient drug testing but excludes TDM use cases

Definitions — presumptive/POC testing characteristics (immunoassay limitations)

Presumptive/POC testing characteristicsImmunoassay-based qualitative or semi-quantitative tests that provide rapid results but have lower sensitivity and specificity and greater risk of false-positives/negatives; positive results often require confirmatory testing

LimitationsPOC tests may not detect certain metabolites and are more prone to false results compared to laboratory immunoassays; clinicians must reference package inserts and lab personnel for assay capabilities

Clinical roleUseful for baseline screening and rapid assessment, with confirmatory definitive testing when results are inconsistent with clinical expectations

Definitions — definitive testing (chromatography + MS) as gold standard

Definitive testing (gold standard)Chromatography with mass spectrometry (GC-MS, LC-MS, LC-MS/MS) considered gold standard for specificity and sensitivity; used to confirm presumptive positives and identify specific drugs/metabolites

UsesAppropriate when results will inform major clinical or nonclinical decisions, or when presumptive tests are inconclusive or conflicting

PerformanceMS-based methods detect more compounds and have superior sensitivity vs immunoassays (cited studies showing higher positives with LC-MS/MS)

Definitions — confirmatory chromatography-based methods (GC-MS, LC-MS, LC-MS/MS)

Confirmatory methods listedGC-MS, LC-MS, LC-MS/MS (chromatography-based confirmatory assays)

ContextRecommended for confirmatory testing of presumptive positives and for high-stakes clinical decisions

Analytic requirementsMethods should include appropriate calibration, internal standards, and QC to ensure reliable identification

Definitions — immunoassay (EIA/POC) limitations

Immunoassay limitationsVariable sensitivity and specificity; documented false-negative rates (e.g., benzodiazepines) and limited ability to detect all agents within a class

False negatives/positives examplesStudies report EIA sensitivity ~78.5% and up to 21% false negatives for opiates in some series; many medications can cross-react

Clinical implicationPositive immunoassay results should be confirmed by definitive testing when inconsistent with clinical context

Definitions — definitive testing purposes and examples

Purposes of definitive testingConfirm presumptive immunoassay results, identify specific substances not detectable by immunoassay, quantify analytes for select clinical questions, and resolve discrepancies

Examples of useDiagnosing/monitoring SUD when results affect treatment, identifying specific drugs in a family, or when presumptive tests are inadequate

Not routine for dosing decisionsQuantitative definitive testing not recommended routinely for determining adherence or dose adjustments due to pharmacokinetic variability

Definitions — quantitative testing role and limitations

Quantitative testing roleReports analyte concentrations and can aid in complex cases (variant metabolism, impurities, multiple opioids) but is not routinely used to determine adherence or dosing

LimitationsPharmacokinetic and pharmacogenetic variability limit correlation between urine concentration and dose; commercial algorithms have low correlation in studies

Appropriate useUse when quantification will change management, to identify variant metabolism, or to investigate potential spiking/alternative exposure sources

Definitions — UDT types (screening and confirmatory modalities)

UDT types — overviewThree main UDT types: immunoassay screening (POC or lab-based), GC/MS confirmatory testing, and LC/MS confirmatory testing

Specimen matricesCommon matrices include urine (preferred), oral fluid, hair, and serum/plasma for selected indications

WorkflowInitial presumptive immunoassay followed by definitive MS-based confirmatory testing when indicated

Definitions — LDT regulatory status under CLIA and lack of FDA approval

LDT regulatory status (CLIA)Laboratory-developed tests (LDTs) are regulated by CMS under CLIA as high-complexity tests and are not FDA-approved; FDA clearance/approval is not required for clinical use

Coverage implicationLDTs lack FDA approval which may affect payer or government policy decisions regarding coverage

Definitions — LDT description and regulatory note

LDT descriptionA test developed and validated by a laboratory and performed in-house (high-complexity under CLIA '88); typically not FDA-approved

Laboratory responsibilityLaboratories must validate and perform appropriate QC for LDTs per CLIA requirements

Definitions — relative performance of immunoassay vs confirmatory testing cited in literature

Relative performance summaryLiterature shows immunoassays have lower sensitivity than LC-MS/MS; EIAs demonstrated ~78.5% sensitivity and LC-MS/MS detected more positives in comparative studies

Implication for practiceUse MS-based definitive methods when highest sensitivity/specificity required (e.g., pain management, SUD monitoring), and confirm unexpected immunoassay results

RecommendationOrthogonal testing strategy (initial immunoassay then MS confirmation) is recommended by multiple organizations